AN ACT to provide for a legislative management study relating to the potential uses of kratom and the implementation of regulations of kratom in the state.
Summary
HB 1566 directs the North Dakota Legislative Management to study kratom during the 2025-26 interim. The study is to examine the potential uses of kratom and possible regulatory approaches in the state, including rules affecting production, manufacturing, distribution, and retail sales of kratom products.
The bill does not itself create a regulatory scheme or change criminal penalties, licensing rules, or consumer protections. Instead, it creates a legislative study process and requires a report back to the 70th Legislative Assembly with findings, recommendations, and any draft legislation needed to carry out those recommendations.
Impact
The bill’s immediate legal effect is limited to authorizing a legislative interim study, so it does not amend existing North Dakota statutes governing controlled substances, commerce, or public health. Any future impact on state law would depend on the recommendations produced by Legislative Management and whether the next legislature enacts follow-up legislation regulating kratom production, manufacturing, distribution, or retail sales.
Sentiment
The voting record suggests generally favorable support for the bill, with strong majorities in both chambers and relatively few opposing votes. The absence of committee transcript material limits insight into detailed debate, but the broad bipartisan vote pattern indicates that lawmakers were at least comfortable with studying the issue rather than adopting immediate regulation. The bill was ultimately filed with the Secretary of State, indicating enactment.
Contention
The main point of potential contention is the policy direction for kratom itself: whether the state should treat it as a product needing regulation, a substance needing tighter controls, or something that warrants more research before action. Supporters appear to favor a measured study of uses and regulatory options, while opponents likely had concerns about expanding state involvement or about kratom’s safety, legality, or market effects. The recorded nays in both chambers suggest some disagreement, but not enough to block the study.